Phase Ia study of a hypoxic cell sensitizer doranidazole (PR-350) in combination with conventional radiotherapy.
Nemoto K, Shibamoto Y, Ohmagari J, Baba Y, Ebe K, Ariga H, Takai Y, Ouchi A, Sasai K, Shinozaki M, Tsujitani M, Sakaguchi M, Yamada S, Sakamoto K.
Nemoto K, et al. Among authors: tsujitani m.
Anticancer Drugs. 2001 Jan;12(1):1-6. doi: 10.1097/00001813-200101000-00001.
Anticancer Drugs. 2001.
PMID: 11272282
Clinical Trial.